AN2 Therapeutics Insider Eric Easom Files Ownership Change

TL;DR

**AN2 insider Eric Easom just reported a change in his stock ownership.**

AI Summary

This Form 4 filing indicates that Eric Easom, a reporting insider, has filed a statement of changes in beneficial ownership of securities for AN2 Therapeutics, Inc. (AN2). The filing, dated March 23, 2026, reports activity as of March 19, 2026. While the filing itself doesn't detail specific transactions, it signals that Easom's ownership stake in AN2 has changed, which is important for investors as insider activity can sometimes signal management's confidence (or lack thereof) in the company's future prospects.

Why It Matters

Insider transaction filings like this can provide clues about how company executives and directors view the stock's value, potentially influencing investor sentiment.

Risk Assessment

Risk Level: low — This filing is purely a notification of a change in beneficial ownership and does not inherently indicate a high risk, as the specific transaction details are not provided in this summary.

Analyst Insight

Investors should look for the detailed transaction information within the full Form 4 document to understand the nature (buy or sell) and size of Eric Easom's change in ownership, as this will provide more actionable insight into his confidence in AN2 Therapeutics.

Key Players & Entities

• Easom Eric (person) — Reporting insider for AN2 Therapeutics, Inc.
• AN2 Therapeutics, Inc. (company) — The issuer of the securities
• 0001914503 (person) — CIK for Eric Easom
• 0001880438 (company) — CIK for AN2 Therapeutics, Inc.

FAQ

Key Financial Figures

• $3.91 — 1. The exercise price of the option is $3.91 per share, representing the closing pri

Filing Documents

• ownership.html (4)
• ownership.xml (4) — 15KB
• 0001193125-26-120192.txt ( ) — 16KB

From the Filing

SEC FORM 4 SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. 1. Name and Address of Reporting Person * Easom Eric (Last) (First) (Middle) C/O AN2 THERAPEUTICS, INC. 1300 EL CAMINO REAL, SUITE 100 (Street) MENLO PARK CALIFORNIA 94025 (City) (State) (Zip) UNITED STATES (Country) 2. Issuer Name and Ticker or Trading Symbol AN2 Therapeutics, Inc. [ ANTX ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner X Officer (give title below) Other (specify below) Chief Executive Officer 2a. Foreign Trading Symbol 3. Date of Earliest Transaction (Month/Day/Year) 03/19/2026 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person 4. If Amendment, Date of Original Filed (Month/Day/Year) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Option (right to buy) $ 3.91 (1) 03/19/2026 A 249,999 (2) 04/29/2031 Common Stock 249,999 (3) 249,999 D Stock Option (right to buy) $ 6.596 03/19/2026 D 249,999 (2) 04/29/2031 Common Stock 249,999 (3) 0 D Stock Option (right to buy) $ 3.91 (1) 03/19/2026 A 225,000 (4) 05/11/2032 Common Stock 225,000 (3) 225,000 D Stock Option (right to buy) $ 17.28 03/19/2026 D 225,000 (4) 05/11/2032 Common Stock 225,000 (3) 0 D Stock Option (right to buy) $ 3.91 (1) 03/19/2026 A 267,650 (5) 02/22/2033 Common Stock 267,650 (3) 267,650 D Stock Option (right to buy) $ 11.99 03/19/2026 D 267,650 (5) 02/22/2033 Common Stock 267,650 (3) 0 D Explanation of Responses: 1. The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "Premium End Date" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The "Premium End Date" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability. 2. The option is fully vested. 3. On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged. 4. The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary measured from March 25, 2022, subject to the Reporting Person's continuous service through each applicable vesting date. 5. The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary measured from January 1, 2023, subject to the Reporting Person's continuous service through each applicable vesting date. /s/ Lucy Day, Attorney-in-Fact for Eric Easom 03/23/2026 ** Signature of Reporting Person Date Reminde

View Full Filing

View this 4 filing on SEC EDGAR